Bristol Cash Flow from Operations

BMYMP
 Stock
  

USD 1,200  10.00  0.84%   

Bristol Myer Squi fundamentals help investors to digest information that contributes to Bristol Myer's financial success or failures. It also enables traders to predict the movement of Bristol OTC Stock. The fundamental analysis module provides a way to measure Bristol Myer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myer otc stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Bristol Cash Flow from Operations Analysis

Bristol Myer's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Operating Cash Flow 
 = 
EBITDA 
-  
Taxes 
More About Cash Flow from Operations | All Equity Analysis

Current Bristol Myer Cash Flow from Operations

    
  5.06 B  
Most of Bristol Myer's fundamental indicators, such as Cash Flow from Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myer Squi is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Compare to competition

In accordance with the recently published financial statements, Bristol Myer Squi has 5.06 B in Cash Flow from Operations. This is much higher than that of the Healthcare sector and 2.1% higher than that of the Drug Manufacturers - Major industry. The cash flow from operations for all United States stocks is significantly lower than that of the firm.

Bristol Cash Flow from Operations Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myer's direct or indirect competition against its Cash Flow from Operations to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myer could also be used in its relative valuation, which is a method of valuing Bristol Myer by comparing valuation metrics of similar companies.
Bristol Myer is currently under evaluation in cash flow from operations category among related companies.

Bristol Fundamentals

About Bristol Myer Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myer Squi's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myer Squi based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bristol Myer without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Shere Portfolio Now

   

Shere Portfolio

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Pair Trading with Bristol Myer

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myer will appreciate offsetting losses from the drop in the long position's value.

Moving against Bristol Myer

-0.84AAPLApple Inc Fiscal Year End 27th of October 2022 PairCorr
-0.79LOWLowes Companies TrendingPairCorr
-0.75CVSCVS Corp TrendingPairCorr
-0.66SBUXStarbucks Corp Fiscal Year End 27th of October 2022 PairCorr
The ability to find closely correlated positions to Bristol Myer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myer Squi to buy it.
The correlation of Bristol Myer is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myer Squi moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Bristol Myer Piotroski F Score and Bristol Myer Altman Z Score analysis. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for analysis

When running Bristol Myer Squi price analysis, check to measure Bristol Myer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myer is operating at the current time. Most of Bristol Myer's value examination focuses on studying past and present price action to predict the probability of Bristol Myer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol Myer's price. Additionally, you may evaluate how the addition of Bristol Myer to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Is Bristol Myer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myer. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bristol Myer Squi is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myer's value that differs from its market value or its book value, called intrinsic value, which is Bristol Myer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myer's market value can be influenced by many factors that don't directly affect Bristol Myer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myer's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol Myer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.